Contribute Try STAT+ Today

In the latest bid to compare drug costs, a new study finds that prices for dozens of cancer medicines were substantially higher when introduced into the U.S. market compared with three wealthy European countries — and they continued to climb at a rate faster than inflation over a decade.

At the same time, the prices in those three other countries — Germany, England, and Switzerland — decreased after accounting for inflation. Moreover, there was no association found between the clinical benefit of the 65 solid tumor and blood cancer medicines, the launch prices, or subsequent price changes in any of the countries, according to the study in JAMA Oncology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment